Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC)

被引：1

作者：

Zer, A. ^{[1
]}

Dudnik, J. ^{[2
]}

Shamai, S. ^{[3
]}

Gottfried, M. ^{[4
]}

Zick, A. ^{[5
,6
]}

Shai, A. ^{[7
]}

Kutiel, T. Shentzer ^{[8
]}

Netiv, E. ^{[9
]}

Yang, F. ^{[9
]}

Sharoni, S. ^{[9
]}

Meng, C. ^{[9
]}

Duic, P. ^{[9
]}

Michel, D. ^{[9
]}

Sbar, E. ^{[9
]}

Shah, J. ^{[9
]}

Kauffman, M. G. ^{[9
]}

Shacham, S. ^{[9
]}

Golan, T. ^{[10
]}

机构：

[1] Davidoff Canc Ctr, Rabin Med Ctr, Med Oncol, Beilinson Campus, Petah Tiqwa, Israel

[2] Soroka Univ, Med Ctr, Oncol Dept, Beer Sheva, Israel

[3] Tel Aviv Sourasky Med Ctr, Oncol Res Unit, Tel Aviv, Israel

[4] Meir Med Ctr, Oncol Inst, Kefar Sava, Israel

[5] Hebrew Univ Jerusalem, Hadassah Med Org, Sharett Inst Oncol, Jerusalem, Israel

[6] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[7] Galilee Med Ctr, Oncol Dept, Nahariyya, Israel

[8] Rambam Hlth Care Campus, Oncol Dept, Haifa, Israel

[9] Karyopharm Therapeut Inc, Newton, MA USA

[10] Chaim Sheba Med Ctr, Oncol Dept, Ramat Gan, Israel

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.1932

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1331P

引用

页码：S1019 / S1019

页数：1